|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 12058 |
FusionGeneSummary for ERP44_CHRDL2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ERP44_CHRDL2 | Fusion gene ID: 12058 | Hgene | Tgene | Gene symbol | ERP44 | CHRDL2 | Gene ID | 23071 | 25884 |
| Gene name | endoplasmic reticulum protein 44 | chordin like 2 | |
| Synonyms | PDIA10|TXNDC4 | BNF1|CHL2 | |
| Cytomap | 9q31.1 | 11q13.4 | |
| Type of gene | protein-coding | protein-coding | |
| Description | endoplasmic reticulum resident protein 44ER protein 44endoplasmic reticulum resident protein 44 kDaprotein disulfide isomerase family A, member 10thioredoxin domain containing 4 (endoplasmic reticulum)thioredoxin domain-containing protein 4 | chordin-like protein 2breast tumor novel factor 1chordin-related protein 2 | |
| Modification date | 20180522 | 20180519 | |
| UniProtAcc | Q9BS26 | Q6WN34 | |
| Ensembl transtripts involved in fusion gene | ENST00000262455, | ENST00000263671, ENST00000376332, ENST00000534159, | |
| Fusion gene scores | * DoF score | 1 X 1 X 1=1 | 3 X 2 X 3=18 |
| # samples | 1 | 3 | |
| ** MAII score | log2(1/1*10)=3.32192809488736 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ERP44 [Title/Abstract] AND CHRDL2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ERP44 | GO:0006457 | protein folding | 11847130 |
| Hgene | ERP44 | GO:0006986 | response to unfolded protein | 11847130 |
| Hgene | ERP44 | GO:0009100 | glycoprotein metabolic process | 11847130 |
| Hgene | ERP44 | GO:0034976 | response to endoplasmic reticulum stress | 11847130 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | HNSC | TCGA-DQ-5624-01A | ERP44 | chr9 | 102814699 | - | CHRDL2 | chr11 | 74429877 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000262455 | ENST00000263671 | ERP44 | chr9 | 102814699 | - | CHRDL2 | chr11 | 74429877 | - |
| In-frame | ENST00000262455 | ENST00000376332 | ERP44 | chr9 | 102814699 | - | CHRDL2 | chr11 | 74429877 | - |
| 5CDS-5UTR | ENST00000262455 | ENST00000534159 | ERP44 | chr9 | 102814699 | - | CHRDL2 | chr11 | 74429877 | - |
Top |
FusionProtFeatures for ERP44_CHRDL2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ERP44 | CHRDL2 |
| Mediates thiol-dependent retention in the earlysecretory pathway, forming mixed disulfides with substrateproteins through its conserved CRFS motif. Inhibits the calciumchannel activity of ITPR1. May have a role in the control ofoxidative protein folding in the endoplasmic reticulum. Requiredto retain ERO1A and ERO1B in the endoplasmic reticulum.{ECO:0000269|PubMed:11847130, ECO:0000269|PubMed:14517240}. | May inhibit BMPs activity by blocking their interactionwith their receptors. Has a negative regulator effect on thecartilage formation/regeneration from immature mesenchymal cells,by preventing or reducing the rate of matrix accumulation (Bysimilarity). Implicated in tumor angiogenesis. May play a roleduring myoblast and osteoblast differentiation, and maturation.{ECO:0000250, ECO:0000269|PubMed:12853144,ECO:0000269|PubMed:15094188}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000263671 | - | 0 | 12 | 109_175 | 27 | 452 | Domain | VWFC 2 |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000263671 | - | 0 | 12 | 250_315 | 27 | 452 | Domain | VWFC 3 |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000263671 | - | 0 | 12 | 31_96 | 27 | 452 | Domain | VWFC 1 |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000376332 | - | 0 | 11 | 109_175 | 27 | 430 | Domain | VWFC 2 |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000376332 | - | 0 | 11 | 250_315 | 27 | 430 | Domain | VWFC 3 |
| Tgene | >CHRDL2 | chr9:102814699 | chr11:74429877 | ENST00000376332 | - | 0 | 11 | 31_96 | 27 | 430 | Domain | VWFC 1 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | >ERP44 | chr9:102814699 | chr11:74429877 | ENST00000262455 | - | 4 | 12 | 30_138 | 95 | 407 | Domain | Thioredoxin |
| Hgene | >ERP44 | chr9:102814699 | chr11:74429877 | ENST00000262455 | - | 4 | 12 | 403_406 | 95 | 407 | Motif | Prevents secretion from ER |
Top |
FusionGeneSequence for ERP44_CHRDL2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000263671_chr11_74429877_-_520aa MHPAVFLSLPDLRCSLLLLVTWVFTPVTTEITSLDTENIDEILNNADVALVNFYADWCRFSQMLHPIFEEASDVIKEEFPNENQVVFARV DCDQHCPDMFCLFHGKRYSPGESWHPYLEPQGLMYCLRCTCSEGAHVSCYRLHCPPVHCPQPVTEPQQCCPKCVEPHTPSGLRAPPKSCQ HNGTMYQHGEIFSAHELFPSRLPNQCVLCSCTEGQIYCGLTTCPEPGCPAPLPLPDSCCQACKDEASEQSDEEDSVQSLHGVRHPQDPCS SDAGRKRGPGTPAPTGLSAPLSFIPRHFRPKGAGSTTVKIVLKEKHKKACVHGGKTYSHGEVWHPAFRAFGPLPCILCTCEDGRQDCQRV TCPTEYPCRHPEKVAGKCCKICPEDKADPGHSEISSTRCPKAPGRVLVHTSVSPSPDNLRRFALEHEASDLVEIYLWKLVKDEETEAQRG >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000376332_chr11_74429877_-_498aa MHPAVFLSLPDLRCSLLLLVTWVFTPVTTEITSLDTENIDEILNNADVALVNFYADWCRFSQMLHPIFEEASDVIKEEFPNENQVVFARV DCDQHCPDMFCLFHGKRYSPGESWHPYLEPQGLMYCLRCTCSEGAHVSCYRLHCPPVHCPQPVTEPQQCCPKCVEPHTPSGLRAPPKSCQ HNGTMYQHGEIFSAHELFPSRLPNQCVLCSCTEGQIYCGLTTCPEPGCPAPLPLPDSCCQACKDEASEQSDEEDSVQSLHGVRHPQDPCS SDAGRKRGPGTPAPTGLSAPLSFIPRHFRPKGAGSTTVKIVLKEKHKKACVHGGKTYSHGEVWHPAFRAFGPLPCILCTCEDGRQDCQRV TCPTEYPCRHPEKVAGKCCKICPEDKADPGHSEISSTRCPKAPGRVLVHTSVSPSPDNLRRFALEHEASDLVEIYLWKLVKGIFHLTQIK |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000263671_chr11_74429877_-_1560nt ATGCATCCTGCCGTCTTCCTATCCTTACCCGACCTCAGATGCTCCCTTCTGCTCCTGGTAACTTGGGTTTTTACTCCTGTAACAACTGAA ATAACAAGTCTTGATACAGAGAATATAGATGAAATTTTAAACAATGCTGATGTTGCTTTAGTAAATTTTTATGCTGACTGGTGTCGTTTC AGTCAGATGTTGCATCCAATTTTTGAGGAAGCTTCCGATGTCATTAAGGAAGAATTTCCAAATGAAAATCAAGTAGTGTTTGCCAGAGTT GATTGTGATCAGCACTGCCCAGACATGTTCTGCCTTTTCCATGGGAAGAGATACTCCCCCGGCGAGAGCTGGCACCCCTACTTGGAGCCA CAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGGGCGCCCATGTGAGTTGTTACCGCCTCCACTGTCCGCCTGTCCACTGCCCC CAGCCTGTGACGGAGCCACAGCAATGCTGTCCCAAGTGTGTGGAACCTCACACTCCCTCTGGACTCCGGGCCCCACCAAAGTCCTGCCAG CACAACGGGACCATGTACCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCCCTCCCGCCTGCCCAACCAGTGTGTCCTCTGCAGC TGCACAGAGGGCCAGATCTACTGCGGCCTCACAACCTGCCCCGAACCAGGCTGCCCAGCACCCCTCCCGCTGCCAGACTCCTGCTGCCAG GCCTGCAAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTCAGGATCCATGTTCC AGTGATGCTGGGAGAAAGAGAGGCCCGGGCACCCCAGCCCCCACTGGCCTCAGCGCCCCTCTGAGCTTCATCCCTCGCCACTTCAGACCC AAGGGAGCAGGCAGCACAACTGTCAAGATCGTCCTGAAGGAGAAACATAAGAAAGCCTGTGTGCATGGCGGGAAGACGTACTCCCACGGG GAGGTGTGGCACCCGGCCTTCCGTGCCTTCGGCCCCTTGCCCTGCATCCTATGCACCTGTGAGGATGGCCGCCAGGACTGCCAGCGTGTG ACCTGTCCCACCGAGTACCCCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTGCCCAGAGGACAAAGCAGACCCTGGC CACAGTGAGATCAGTTCTACCAGGTGTCCCAAGGCACCGGGCCGGGTCCTCGTCCACACATCGGTATCCCCAAGCCCAGACAACCTGCGT CGCTTTGCCCTGGAACACGAGGCCTCGGACTTGGTGGAGATCTACCTCTGGAAGCTGGTAAAAGATGAGGAAACTGAGGCTCAGAGAGGT GAAGTACCTGGCCCAAGGCCACACAGCCAGAATCTTCCACTTGACTCAGATCAAGAAAGTCAGGAAGCAAGACTTCCAGAAAGAGGCACA GCACTTCCGACTGCTCGCTGGCCCCCACGAAGGTCACTGGAACGTCTTCCTAGCCCAGACCCTGGAGCTGAAGGTCACGGCCAGTCCAGA >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000376332_chr11_74429877_-_1494nt ATGCATCCTGCCGTCTTCCTATCCTTACCCGACCTCAGATGCTCCCTTCTGCTCCTGGTAACTTGGGTTTTTACTCCTGTAACAACTGAA ATAACAAGTCTTGATACAGAGAATATAGATGAAATTTTAAACAATGCTGATGTTGCTTTAGTAAATTTTTATGCTGACTGGTGTCGTTTC AGTCAGATGTTGCATCCAATTTTTGAGGAAGCTTCCGATGTCATTAAGGAAGAATTTCCAAATGAAAATCAAGTAGTGTTTGCCAGAGTT GATTGTGATCAGCACTGCCCAGACATGTTCTGCCTTTTCCATGGGAAGAGATACTCCCCCGGCGAGAGCTGGCACCCCTACTTGGAGCCA CAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGGGCGCCCATGTGAGTTGTTACCGCCTCCACTGTCCGCCTGTCCACTGCCCC CAGCCTGTGACGGAGCCACAGCAATGCTGTCCCAAGTGTGTGGAACCTCACACTCCCTCTGGACTCCGGGCCCCACCAAAGTCCTGCCAG CACAACGGGACCATGTACCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCCCTCCCGCCTGCCCAACCAGTGTGTCCTCTGCAGC TGCACAGAGGGCCAGATCTACTGCGGCCTCACAACCTGCCCCGAACCAGGCTGCCCAGCACCCCTCCCGCTGCCAGACTCCTGCTGCCAG GCCTGCAAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTCAGGATCCATGTTCC AGTGATGCTGGGAGAAAGAGAGGCCCGGGCACCCCAGCCCCCACTGGCCTCAGCGCCCCTCTGAGCTTCATCCCTCGCCACTTCAGACCC AAGGGAGCAGGCAGCACAACTGTCAAGATCGTCCTGAAGGAGAAACATAAGAAAGCCTGTGTGCATGGCGGGAAGACGTACTCCCACGGG GAGGTGTGGCACCCGGCCTTCCGTGCCTTCGGCCCCTTGCCCTGCATCCTATGCACCTGTGAGGATGGCCGCCAGGACTGCCAGCGTGTG ACCTGTCCCACCGAGTACCCCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTGCCCAGAGGACAAAGCAGACCCTGGC CACAGTGAGATCAGTTCTACCAGGTGTCCCAAGGCACCGGGCCGGGTCCTCGTCCACACATCGGTATCCCCAAGCCCAGACAACCTGCGT CGCTTTGCCCTGGAACACGAGGCCTCGGACTTGGTGGAGATCTACCTCTGGAAGCTGGTAAAAGGAATCTTCCACTTGACTCAGATCAAG AAAGTCAGGAAGCAAGACTTCCAGAAAGAGGCACAGCACTTCCGACTGCTCGCTGGCCCCCACGAAGGTCACTGGAACGTCTTCCTAGCC |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000263671_chr11_74429877_-_1829nt GAAGTGAGGGTGTGAGAGGCCTCTCTGGAAGTTGTCCCGGGTGTTCGCCGCTGGAGCCCGGGTCGAGAGGACGAGGTGCCGCTGCCTGGA GAATCCTCCGCTGCCGTCGGCTCCCGGAGCCCAGCCCTTTCCTAACCCAACCCAACCTAGCCCAGTCCCAGCCGCCAGCGCCTGTCCCTG TCACGGACCCCAGCGTTACCATGCATCCTGCCGTCTTCCTATCCTTACCCGACCTCAGATGCTCCCTTCTGCTCCTGGTAACTTGGGTTT TTACTCCTGTAACAACTGAAATAACAAGTCTTGATACAGAGAATATAGATGAAATTTTAAACAATGCTGATGTTGCTTTAGTAAATTTTT ATGCTGACTGGTGTCGTTTCAGTCAGATGTTGCATCCAATTTTTGAGGAAGCTTCCGATGTCATTAAGGAAGAATTTCCAAATGAAAATC AAGTAGTGTTTGCCAGAGTTGATTGTGATCAGCACTGCCCAGACATGTTCTGCCTTTTCCATGGGAAGAGATACTCCCCCGGCGAGAGCT GGCACCCCTACTTGGAGCCACAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGGGCGCCCATGTGAGTTGTTACCGCCTCCACT GTCCGCCTGTCCACTGCCCCCAGCCTGTGACGGAGCCACAGCAATGCTGTCCCAAGTGTGTGGAACCTCACACTCCCTCTGGACTCCGGG CCCCACCAAAGTCCTGCCAGCACAACGGGACCATGTACCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCCCTCCCGCCTGCCCA ACCAGTGTGTCCTCTGCAGCTGCACAGAGGGCCAGATCTACTGCGGCCTCACAACCTGCCCCGAACCAGGCTGCCCAGCACCCCTCCCGC TGCCAGACTCCTGCTGCCAGGCCTGCAAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGAC ATCCTCAGGATCCATGTTCCAGTGATGCTGGGAGAAAGAGAGGCCCGGGCACCCCAGCCCCCACTGGCCTCAGCGCCCCTCTGAGCTTCA TCCCTCGCCACTTCAGACCCAAGGGAGCAGGCAGCACAACTGTCAAGATCGTCCTGAAGGAGAAACATAAGAAAGCCTGTGTGCATGGCG GGAAGACGTACTCCCACGGGGAGGTGTGGCACCCGGCCTTCCGTGCCTTCGGCCCCTTGCCCTGCATCCTATGCACCTGTGAGGATGGCC GCCAGGACTGCCAGCGTGTGACCTGTCCCACCGAGTACCCCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTGCCCAG AGGACAAAGCAGACCCTGGCCACAGTGAGATCAGTTCTACCAGGTGTCCCAAGGCACCGGGCCGGGTCCTCGTCCACACATCGGTATCCC CAAGCCCAGACAACCTGCGTCGCTTTGCCCTGGAACACGAGGCCTCGGACTTGGTGGAGATCTACCTCTGGAAGCTGGTAAAAGATGAGG AAACTGAGGCTCAGAGAGGTGAAGTACCTGGCCCAAGGCCACACAGCCAGAATCTTCCACTTGACTCAGATCAAGAAAGTCAGGAAGCAA GACTTCCAGAAAGAGGCACAGCACTTCCGACTGCTCGCTGGCCCCCACGAAGGTCACTGGAACGTCTTCCTAGCCCAGACCCTGGAGCTG AAGGTCACGGCCAGTCCAGACAAAGTGACCAAGACATAACAAAGACCTAACAGTTGCAGATATGAGCTGTATAATTGTTGTTATTATATA >In-frame_ERP44_ENST00000262455_chr9_102814699_-_CHRDL2_ENST00000376332_chr11_74429877_-_1774nt GAAGTGAGGGTGTGAGAGGCCTCTCTGGAAGTTGTCCCGGGTGTTCGCCGCTGGAGCCCGGGTCGAGAGGACGAGGTGCCGCTGCCTGGA GAATCCTCCGCTGCCGTCGGCTCCCGGAGCCCAGCCCTTTCCTAACCCAACCCAACCTAGCCCAGTCCCAGCCGCCAGCGCCTGTCCCTG TCACGGACCCCAGCGTTACCATGCATCCTGCCGTCTTCCTATCCTTACCCGACCTCAGATGCTCCCTTCTGCTCCTGGTAACTTGGGTTT TTACTCCTGTAACAACTGAAATAACAAGTCTTGATACAGAGAATATAGATGAAATTTTAAACAATGCTGATGTTGCTTTAGTAAATTTTT ATGCTGACTGGTGTCGTTTCAGTCAGATGTTGCATCCAATTTTTGAGGAAGCTTCCGATGTCATTAAGGAAGAATTTCCAAATGAAAATC AAGTAGTGTTTGCCAGAGTTGATTGTGATCAGCACTGCCCAGACATGTTCTGCCTTTTCCATGGGAAGAGATACTCCCCCGGCGAGAGCT GGCACCCCTACTTGGAGCCACAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGGGCGCCCATGTGAGTTGTTACCGCCTCCACT GTCCGCCTGTCCACTGCCCCCAGCCTGTGACGGAGCCACAGCAATGCTGTCCCAAGTGTGTGGAACCTCACACTCCCTCTGGACTCCGGG CCCCACCAAAGTCCTGCCAGCACAACGGGACCATGTACCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCCCTCCCGCCTGCCCA ACCAGTGTGTCCTCTGCAGCTGCACAGAGGGCCAGATCTACTGCGGCCTCACAACCTGCCCCGAACCAGGCTGCCCAGCACCCCTCCCGC TGCCAGACTCCTGCTGCCAGGCCTGCAAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGAC ATCCTCAGGATCCATGTTCCAGTGATGCTGGGAGAAAGAGAGGCCCGGGCACCCCAGCCCCCACTGGCCTCAGCGCCCCTCTGAGCTTCA TCCCTCGCCACTTCAGACCCAAGGGAGCAGGCAGCACAACTGTCAAGATCGTCCTGAAGGAGAAACATAAGAAAGCCTGTGTGCATGGCG GGAAGACGTACTCCCACGGGGAGGTGTGGCACCCGGCCTTCCGTGCCTTCGGCCCCTTGCCCTGCATCCTATGCACCTGTGAGGATGGCC GCCAGGACTGCCAGCGTGTGACCTGTCCCACCGAGTACCCCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTGCCCAG AGGACAAAGCAGACCCTGGCCACAGTGAGATCAGTTCTACCAGGTGTCCCAAGGCACCGGGCCGGGTCCTCGTCCACACATCGGTATCCC CAAGCCCAGACAACCTGCGTCGCTTTGCCCTGGAACACGAGGCCTCGGACTTGGTGGAGATCTACCTCTGGAAGCTGGTAAAAGGAATCT TCCACTTGACTCAGATCAAGAAAGTCAGGAAGCAAGACTTCCAGAAAGAGGCACAGCACTTCCGACTGCTCGCTGGCCCCCACGAAGGTC ACTGGAACGTCTTCCTAGCCCAGACCCTGGAGCTGAAGGTCACGGCCAGTCCAGACAAAGTGACCAAGACATAACAAAGACCTAACAGTT |
Top |
FusionGenePPI for ERP44_CHRDL2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| ERP44 | CD40, ERO1L, ERO1LB, USP46, USP32, UIMC1, RASSF5, ELAVL1, CKB, CNN2, FERMT2, G6PD, FHL2, ISOC1, LARS, NUDCD1, OSGEP, PAK2, PDCD10, PFAS, PLD3, TBCB, UBFD1, VCL, YWHAZ, FUS, CUL7, YAP1, PNPO, SNX2, NTRK1, ALDH7A1, NRD1, PIAS1, FAM13A, PACSIN2, ID1, EPB41L4B, KMT2C, COPS7B, TMEM189, MCM2, MCM5, IL12B, CDC73, DUSP8, ZFPM1, MEX3A, STXBP4, PXDN, FAM73A, TGFB1, DCP1B, ZNF212, DAPK1, BCOR, ZNF777, ZMYM1, TNIP1, ITPKC, GNL3L, RPIA, RBBP8, UBE2Q1, HOXA5, POLD2, SUMF1, FIGN, FN1, CASP3, BTD, PRIM2, PTPRN, PTPRO, EDEM3 | CHRDL2 | INHBA |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Hgene | ERP44 | chr9:102814699 | chr11:74429877 | ENST00000262455 | - | 4 | 12 | 236_285 | 95 | 407 | ITPR1 |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ERP44_CHRDL2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ERP44_CHRDL2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ERP44 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|